Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations

Autor: Ferrari A., Bussaglia E., Úbeda J., Facchini L., Aventin A., Sierra J., Nomdedéu J.F.
Rok vydání: 2012
Předmět:
CD135 antigen
cancer patient
Antigens
CD34
HLA DR antigen
cytogenetics
Leukemia
Promyelocytic
Acute
genetic variability
CD34 antigen
gene mutation
promyelocytic leukemia
thrombopoietin receptor
predictive value
adult
article
Nuclear Proteins
CD15 antigen
Flow Cytometry
Fucosyltransferases
acute granulocytic leukemia
Neoplasm Proteins
aged
Leukemia
Myeloid
Acute
female
leukemia cell
priority journal
diagnostic test
retinoic acid receptor alpha
nucleophosmin
immunoreactivity
Proto-O
Antigens
CD15
CD2 antigen
Immunophenotyping
reverse transcription polymerase chain reaction
Diagnosis
Differential
fluorescence analysis
male
Antigens
CD
Antigens
Neoplasm
Humans
controlled study
diagnostic test accuracy study
human
microsomal aminopeptidase
human cell
CD33 antigen
HLA-DR Antigens
major clinical study
fms-Like Tyrosine Kinase 3
sensitivity and specificity
molecular genetics
antigen expression
Zdroj: HEMATOLOGICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
ISSN: 0278-0232
Popis: Acute promyelocytic leukaemia (APL) is a unique clinicobiologic entity that can be successfully treated with All-trans Retinoic Acid ATRA-based regimens. Some cases of acute myeloid leukaemia (AML) with nucleophosmin (NPM) mutations have an immunophenotype that is similar to APL. The objective of the study is to compare antigenic expression in a group of APL patients with that in AML patients with NPM mutations and an APL-like immunophenotype (CD15- CD34- HLA-DR-). A consecutive series of 40 APL and 12 NPM patients with an APL-like phenotype were included in the study. Immunophenotypic patterns were investigated by multiparametric flow cytometry. Promyelocytic leukaemia-retinoic acid receptor-a transcript type, NPM and FLT3 mutations were investigated using conventional methods. Statistically significant differences were found between APL and NPM-mutated AML in CD33, CD13, CD2 and CD110 reactivity. CD2 expression was absent in every patient with NPM-mutated AML. In addition, mean fluorescence intensity and the coefficient of variation (cv) of CD33 and CD13 showed statistical differences between the two groups for CD33 (p=0.007) and a trend to significance for CD13 (p=0.05). Furthermore, among 45 evaluable patients, CD110 expression statistically differentiates between the two groups: [2/33 (6%) in the APL group and 8/12 (66.6%) in the NPM-mutated AML (p=0.014)]. However, these traits were subtle, raising the possibility of practical diagnostic challenges. In conclusion, CD110 and CD33 reactivity may be useful to distinguish APL from NPM-mutated AML with CD15, CD34 and HLA-DR negativity. Nevertheless, cytogenetic and molecular characterization is necessary to establish the accurate diagnosis of AML. © 2011 John Wiley & Sons, Ltd.
Databáze: OpenAIRE
Externí odkaz: